ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $899,000 | -0.6% | 17,330 | -9.4% | 0.00% | 0.0% |
| Q2 2022 | $904,000 | -12.9% | 19,123 | +18.7% | 0.00% | 0.0% |
| Q1 2022 | $1,038,000 | +86.0% | 16,114 | +116.1% | 0.00% | 0.0% |
| Q4 2021 | $558,000 | +121.4% | 7,457 | +46.2% | 0.00% | – |
| Q1 2021 | $252,000 | -10.6% | 5,101 | -23.8% | 0.00% | – |
| Q4 2020 | $282,000 | +2.5% | 6,694 | +11.3% | 0.00% | – |
| Q3 2020 | $275,000 | -65.9% | 6,017 | -62.5% | 0.00% | -100.0% |
| Q2 2020 | $806,000 | +95.6% | 16,060 | +100.2% | 0.00% | – |
| Q1 2020 | $412,000 | +33.3% | 8,022 | +60.6% | 0.00% | – |
| Q4 2019 | $309,000 | +17.9% | 4,996 | +14.5% | 0.00% | – |
| Q3 2019 | $262,000 | +291.0% | 4,362 | +450.1% | 0.00% | – |
| Q2 2019 | $67,000 | -67.6% | 793 | -63.5% | 0.00% | – |
| Q1 2019 | $207,000 | -1.9% | 2,170 | -27.2% | 0.00% | -100.0% |
| Q4 2018 | $211,000 | -13.9% | 2,979 | +4.1% | 0.00% | 0.0% |
| Q3 2018 | $245,000 | – | 2,863 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |